This page shows the latest lebrikizumab news and features for those working in and with pharma, biotech and healthcare.
The Dermira deal saw Lilly gain both a marketed drug – medicated cloth Qbrexza (glycopyrronium) for uncontrolled excessive underarm sweating – as well as pipeline candidate lebrikizumab for atopic dermatitis, which is currently
The pharma giant is also set to gain an additional phase 3 candidate from the deal – lebrikizumab, a monoclonal antibody designed to bind to IL-13 that is being evaluated for ... Roche had been developing lebrikizumab as a potential treatment for
The option deal comes amid an expansionist phase for Almirall, which exercised an option to buy Dermira’s anti-IL-13 antibody lebrikizumab – heading for phase 3 testing in atopic dermatitis
There are a number of drugs coming through the collective industry pipeline as well, including IL-13 inhibitors from Dermira (lebrikizumab) and Leo Pharma (tralokinumab) and oral JAK inhibitors such as
Also in its pipeline is an injectable drug for atopic dermatitis - I L-13 inhibitor lebrikizumab - which was developed by Roche and licensed to Dermira in a deal valued at up ... That programme is in mid-stage clinical testing. Even if it successfully
The failure of tralokinumab hasn’t come out of the blue, as another trial (STRATOS 1) also failed to hit the mark, and other IL-13 inhibitors - including Roche’s lebrikizumab
More from news
Approximately 3 fully matching, plus 13 partially matching documents found.
This brings a much needed boost to its respiratory portfolio, which currently consists of Pulmozyme (cystic fibrosis) and Xolair (severe asthma) and products in clinical development, eg lebrikizumab (severe asthma).
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...